Sanofi - CSR Newsletter #6 - July 2015
To access the interactive newsletter, click here
"Connecting Nurses": Joining together to improve patient lives
IMPROVING ACCESS TO HEALTHCARE
EVERY MINUTE IN AFRICA, A CHILD DIES OF MALARIA... WHAT DOES SANOFI DO?
More than 7.7 million children reached
The "Schoolchildren against Malaria" program of Sanofi is active in 15 African countries, providing teachers with a range of edutainment tools designed to raise awareness of the disease. In Niger alone, some 50 schools are taking part in this program, with 5,000 children using their new-found knowledge to help educate their families and communities about malaria.
"Patent for Humanity": Sanofi rewarded
Sanofi received the prestigious “Patent for Humanity” award from the United States Patent and Trademark Office (USPTO) at the White House, for its semi-synthetic artemisinin, a key component of the production of anti-malarial treatments recommended by the World Health Organization.
Taking down MS (Multiple Sclerosis) barriers
On this year’s World MS day, Genzyme continues to join the global MS community to take down MS barriers and raise awareness of this disease. Beyond its ongoing research, clinical development programs and commercial therapies, Genzyme is committed to improving the lives of people living with MS through real-world data collection, support for caregivers and patients, as well as awareness programs globally.
>> To know more about Genzyme's programs
Eliminating sleeping sickness – a successful partnership
Thanks to our partnership with the World Health Organization launched in 2001 to combat sleeping sickness, over 30 million people have undergone screening and over 180,000 patients have been treated for the disease, which is fatal if left untreated.
>> To know more about our partnerships
REDUCING HEALTHCARE INEQUALITIES
Solidarity with Nepal
Facing the earthquake that hit Nepal on April 25th, Sanofi has coordinated several actions including donations of medicines and vaccines. The Sanofi Espoir Foundation has donated
€ 100,000 to selected partners, and a call to generosity was launched internally helping collect
€ 200,000 thanks to the matching donations from the Group.
PATIENT SAFETY
Fighting counterfeit medicines
The Sanofi Central Anti-Counterfeit Laboratory is a dedicated team of specialists who use
state-of-the-art technologies to analyze suspect product samples found on the market, as well as packaging and product inserts. Since its creation in 2008, more than 30,000 entries were analyzed in order to detect potential counterfeit products.
Access the interactive article for more content, which includes videos shared by global employees about diversity.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
